378 related articles for article (PubMed ID: 22053916)
21. [Effect of pitavastatin on macrophage cholesterol metabolism].
Akisato Y; Ishii I; Kitahara M; Tamaki T; Saito Y; Kitada M
Yakugaku Zasshi; 2008 Mar; 128(3):357-63. PubMed ID: 18311054
[TBL] [Abstract][Full Text] [Related]
22. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
Teramoto T
Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
[TBL] [Abstract][Full Text] [Related]
25. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
Barrios V; Escobar C; Zamorano JL
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
[TBL] [Abstract][Full Text] [Related]
26. [Do the pleiotropic effects of statins have a clinical significance?].
Vergès B
Arch Mal Coeur Vaiss; 2004 Dec; 97(12):1231-5. PubMed ID: 15669365
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
28. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
29. Novel statins: pharmacological and clinical results.
Bolego C; Poli A; Cignarella A; Catapano AL; Paoletti R
Cardiovasc Drugs Ther; 2002 May; 16(3):251-7. PubMed ID: 12374904
[TBL] [Abstract][Full Text] [Related]
30. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
[TBL] [Abstract][Full Text] [Related]
33. Improvement of endothelial function by pitavastatin: a meta-analysis.
Katsiki N; Reiner Ž; Tedeschi Reiner E; Al-Rasadi K; Pirro M; Mikhailidis DP; Sahebkar A
Expert Opin Pharmacother; 2018 Feb; 19(3):279-286. PubMed ID: 29334477
[TBL] [Abstract][Full Text] [Related]
34. NK-104: a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Mabuchi H; Saito Y
Expert Opin Investig Drugs; 2000 Nov; 9(11):2653-61. PubMed ID: 11060827
[TBL] [Abstract][Full Text] [Related]
35. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
Nozue T; Michishita I; Ito Y; Hirano T
J Atheroscler Thromb; 2008 Jun; 15(3):146-53. PubMed ID: 18603821
[TBL] [Abstract][Full Text] [Related]
36. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo.
Kojima Y; Ishida T; Sun L; Yasuda T; Toh R; Rikitake Y; Fukuda A; Kume N; Koshiyama H; Taniguchi A; Hirata K
Cardiovasc Res; 2010 Jul; 87(2):385-93. PubMed ID: 20045866
[TBL] [Abstract][Full Text] [Related]
37. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104).
Han J; Parsons M; Zhou X; Nicholson AC; Gotto AM; Hajjar DP
Circulation; 2004 Nov; 110(22):3472-9. PubMed ID: 15557368
[TBL] [Abstract][Full Text] [Related]
38. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Ito MK; Talbert RL; Tsimikas S
Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
[TBL] [Abstract][Full Text] [Related]
39. New evidence on pitavastatin: efficacy and safety in clinical studies.
Teramoto T; Shimano H; Yokote K; Urashima M
Expert Opin Pharmacother; 2010 Apr; 11(5):817-28. PubMed ID: 20201733
[TBL] [Abstract][Full Text] [Related]
40. [Cardiovascular prevention and pitavastatin].
Kayıkçıoğlu M
Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):8-12. PubMed ID: 28952472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
